5.6% annual growth forecast for multiple myeloma drug market to 2020

21 December 2011

Driven by further penetration of Celgene’s Revlimid (lenalidomide) into the first-line setting and the launch of premium-priced emerging therapies, the multiple myeloma drug market will experience robust 5.6% annual growth from 2010 to 2020 in the leading markets of the USA, France, Germany, Italy, Spain, the UK and Japan, according to a new report from health care advisory firm Decision Resources.

Three agents currently dominate sales in the myeloma market: Celgene’s Revlimid, Takeda/Janssen-Cilag/Janssen’s Velcade (bortezomib), and Celgene’s Thalidomide/Thalomid and Fujimoto Seiyaku’s Thaled (thalidomide). In a report issued last year, Decision Resources forecast that the multiple myeloma market would rise from a value of $2.1 billion in 2008 to $5.3 billion in 2018.

Revlimid to eclipse Velcade

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical